INSTITUTO DE INVESTIGACIONES BIOTECNOLOGICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Characterization of EO771-tumor as an in vivo model to study breast cancer cell - immune system interactions
CASTILLO LILIAN FEDRA; COSO OMAR ADRIAN; SIMIAN MARINA; DE LA MATA, MANUEL; PALAVECINO MARCOS; RODRIGUEZ-SEGUI SANTIAGO; KORDON EDITH; GATELLI ALBANA; FEDEDA, JUAN PABLO; PAULA A. AGUIRRE; MEISS ROBERTO; WERTHEIMER EVA; ERRASTI ANDREA EMILSE; CARRERA-SILVA ANTONIO E.
Congreso; Reunion Anual Sociedad Argentina de Investigación Bioquímica y Biología Molecular; 2020
Mouse model systems have been key in understanding novel mechanisms underpinning breast cancer development and delivering new therapies. Among them, the EO771 triple negative-like cell line is emerging as a new spontaneous model to study breast cancer in the C57BL/6 mice background. Here, we confirm the hormone-dependency and we characterize the changes in the immune and inflammatory compartments associated to the progression states of EO771 tumor growth using flow cytometry.Tumor-associated macrophages (TAMs) are relevant cells of the tumor microenvironment, and in the clinic M2 subtypes associated with the promotion of tumor progression. By interrogating the myeloid compartment present in the EO771-tumor model, we found that tumor progression associates with increased M2 macrophage polarization. Interestingly, we observed a decrease in MHCII+ Antigen Presenting Cells (APCs) in advanced tumors, which is consistent with tumor-mediated immunosuppression by antigen presentation inhibition. Furthermore, by investigating the tumor infiltrating lymphocytes (TILs) landscape, we observed a marked increase in the CD4+/CD8+ ratio during the tumor progression, mimicking the high CD4+/CD8+ ratios associated with poor prognosis in triple negative breast cancer (TNBC) patients. Moreover, CD4+ PD1high TILs population is increase in later stages, which is consistent with CD4+ TIL exhaustion during tumor progression.In summary, we found that EO771-tumor progression elicits key features of the clinically observed immune system response in TNBC, making it an ideal model to study TNBC tumor-immune system interactions